Why Is ZTS Up Today?

This afternoon we watched Zoetis rise 1.6% to a price of $178.59 per share. The large-cap Pharmaceutical company is now trading -16.9% below its average target price of $214.92. Analysts have set target prices ranging from $180.0 to $260.0 per share for Zoetis, and have given the stock an average rating of buy.

The stock has a very low short interest at 1.1%, and a short ratio of 2.69. The company's insiders own 0.2% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 94.4% of Zoetis's shares being owned by this investor type.

Institutions Invested in Zoetis

Date Reported Holder Percentage Shares Value
2022-12-31 Blackrock Inc. 9% 40,083,985 $7,158,598,734
2022-12-31 Vanguard Group, Inc. (The) 8% 36,850,763 $6,581,177,629
2022-12-31 State Street Corporation 4% 19,868,824 $3,548,373,205
2022-12-31 AllianceBernstein, L.P. 4% 19,510,212 $3,484,328,689
2022-12-31 State Farm Mutual Automobile Insurance Co 4% 17,134,819 $3,060,107,262
2022-12-31 Bank of America Corporation 3% 14,146,596 $2,526,440,527
2022-12-31 Capital International Investors 3% 12,651,002 $2,259,342,400
2022-12-31 Wellington Management Group, LLP 3% 11,616,674 $2,074,621,767
2022-12-31 Morgan Stanley 2% 10,872,704 $1,941,756,167
2022-12-31 Geode Capital Management, LLC 2% 9,712,273 $1,734,514,799
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.